Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 7/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16933460 | 0.94 | CA2 (0.31) | KDM1ACCR5CA2NPC1RAB9A | |
| SCHEMBL16933535 | 0.81 | MEN1 (0.35) | CHRM1CHRM3CHRM5MEN1KMT2A | |
| SCHEMBL16007060 | 0.81 | CHRM1 (0.38) | CHRM1CHRM3CHRM5CHRM2 | |
| SCHEMBL16933677 | 0.77 | CHRM5 (0.40) | CHRM1CHRM3CHRM5MEN1KMT2A | |
| SCHEMBL16933657 | 0.77 | CHRM5 (0.41) | CHRM1CHRM3CHRM5MEN1KMT2A | |
| SCHEMBL29397422 | 0.75 | NTMT1 (0.44) | CHRM3 | |
| SCHEMBL29398893 | 0.72 | NTMT1 (0.37) | — | |
| SCHEMBL16933493 | 0.69 | MEN1 (0.36) | CHRM1CHRM3CHRM5MEN1KMT2A | |
| SCHEMBL16933480 | 0.69 | KCNH2 (0.43) | CHRM1CHRM3CHRM5MEN1KMT2A | |
| SCHEMBL15578134 | 0.68 | CA2 (0.40) | MEN1KMT2ACA2MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | KDM1A 3939/4885CHRM1 4870/4885CHRM3 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.